Efficacy of sulodexide in the treatment of high-risk atherosclerotic stroke
HE Min
ZHANG Qiang
CHEN Houqin
CUI Fan
Abstract：Objective To explore the early efficacy and safety of sulodexide in the treatment of patients with high-risk atherosclerotic stroke.Methods A total of 150 high-risk atherosclerotic stroke patients admitted to the First People's Hos-pital of Wuhu from September 2020 to September 2023 were enrolled in this prospective study.They were randomly assigned to the treatment group(n=76)and the control group(n=74)using a random number table method.The control group received stan-dard treatment as per current guidelines,including risk factor management,antiplatelet therapy,lipid-lowering,blood pressure and blood glucose control,and rehabilitation.The treatment group received sulodexide injection at a dose of 600 LSU/day via intravenous infusion for 15 days,in addition to the standard regimen given to the control group.All patients continued with the standard treatment protocol until the end of follow-up.The neurological function scores of patients in the control group and the treatment group at discharge and 90 days after onset(including National Institutes of Health Stroke Scale(NIHSS)scores and modified Rankin Scale(mRS)scores)at discharge and 90 days after onset,as well as the early stroke progression rate and early neurological deterioration rate at discharge,the good prognosis rate,stroke recurrence rate,vascular stenosis rate,bleeding event occurrence rate and all-cause mortality rate at 90 days after onset were compared between the control group and the treatment group.Results At discharge,the NIHSS and mRS scores of the treatment group((2.97±2.25)points and(1.69±1.07)points,respectively)were significantly lower than those of the control group((4.91±3.67)points and(2.24±1.04)points,respectively)(t=15.07,10.12,both P＜0.05).At 90 days after onset,the NIHSS and mRS scores of the treatment group((2.57±1.91)points and(1.56±1.06)points,respectively)were significantly lower than those of the control group((3.50±2.68)points and(2.07±0.98)points,respectively)(t=5.915,9.211,both P＜0.05).The early stroke progression rate and early neurological deterioration rate in the treatment group were 7.89%(6/76)and 10.53%(8/76),respectively,lower than those in the control group(21.62%(16/74)vs 22.97%(17/74)),and the differences were statistically significant(χ2=3.334,4.182,both P＜0.05).At discharge,the bleeding events rate in the treatment group was 9.21%(7/76),increasing to 17.11%(13/76)at 90 days,and the all-cause mortality rate was 1.32%(1/76).And no statistically significant differences were observed compared with the control group(bleeding event rates:8.11%(6/74)at discharge and 13.51%(10/74)at 90 days;mortality:2.70%(2/74))(χ2=0.735,0.373 and 0.368,all P＞0.05).The good prognosis rate at 90 days in the treatment group was 80.26%(61/76),significantly higher than that in the control group(62.16%(46/74)),with a statistically significant difference(χ2=6.180,P＜0.05).There were no statistically significant differences between the two groups in stroke recurrence rates at 90 days or in vascular stenosis rates at admission and 90 days post-onset(all P＞0.05).Conclusion Sulodexide can reduce the early stroke progression rate and early neurological deterioration rate in pa-tients with high-risk atherosclerotic stroke,improve neurological function scores at discharge and 90 days,and improve the good prognosis rate of patients at 90 days,with good safety.
Keywords：sulodexidestrokestroke progressionearly neurological deteriorationatherosclerosis
Publication Date：2025-12-25
Online Publishing Date：2026-01-07(First online date of this platform, not the publication date of the document)
Pages：5( 1502-1506 )